Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge

doi:10.1016/j.vaccine.2019.10.049

Title: Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge

Full Record
Other Related Research

Authors:: Russo, Andrew T.; Berhanu, Aklile; Bigger, Catherine B.; Prigge, Jon; Silvera, Peter M.; Grosenbach, Douglas W.; Hruby, Dennis

Publication Date:: 2020-01-01

Sponsoring Org.:: USDOE

OSTI Identifier:: 1581454

Grant/Contract Number:: 5R44AI075747

Resource Type:: Published Article

Journal Name:: Vaccine

Additional Journal Information:: Journal Name: Vaccine Journal Volume: 38 Journal Issue: 3; Journal ID: ISSN 0264-410X

Publisher:: Elsevier

Country of Publication:: United Kingdom

Language:: English

Citation Formats


                    Russo, Andrew T., Berhanu, Aklile, Bigger, Catherine B., Prigge, Jon, Silvera, Peter M., Grosenbach, Douglas W., and Hruby, Dennis. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.  United Kingdom: N. p., 2020. 
        Web.  doi:10.1016/j.vaccine.2019.10.049.

Copy to clipboard


                    Russo, Andrew T., Berhanu, Aklile, Bigger, Catherine B., Prigge, Jon, Silvera, Peter M., Grosenbach, Douglas W., & Hruby, Dennis. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.  United Kingdom.  doi:10.1016/j.vaccine.2019.10.049.

Copy to clipboard


                    Russo, Andrew T., Berhanu, Aklile, Bigger, Catherine B., Prigge, Jon, Silvera, Peter M., Grosenbach, Douglas W., and Hruby, Dennis. Wed .  
        "Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge".  United Kingdom.  doi:10.1016/j.vaccine.2019.10.049.

Copy to clipboard


                    
@article{osti_1581454,

  title        = {Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge},

  author       = {Russo, Andrew T. and Berhanu, Aklile and Bigger, Catherine B. and Prigge, Jon and Silvera, Peter M. and Grosenbach, Douglas W. and Hruby, Dennis},

  abstractNote = {},

  doi          = {10.1016/j.vaccine.2019.10.049},

  journal      = {Vaccine},

  number       = 3,

  volume       = 38,

  place        = {United Kingdom},

  year         = {2020},

  month        = {1}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Publisher's Version of Record
DOI: 10.1016/j.vaccine.2019.10.049

Other availability

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge

Journal Article Bukreyev, Alexander ; Marzi, Andrea ; Feldmann, Friederike ; ... - Virology

We generated a new live-attenuated vaccine against Ebola virus (EBOV) based on a chimeric virus HPIV3/{delta}F-HN/EboGP that contains the EBOV glycoprotein (GP) as the sole transmembrane envelope protein combined with the internal proteins of human parainfluenza virus type 3 (HPIV3). Electron microscopy analysis of the virus particles showed that they have an envelope and surface spikes resembling those of EBOV and a particle size and shape resembling those of HPIV3. When HPIV3/{delta}F-HN/EboGP was inoculated via apical surface of an in vitro model of human ciliated airway epithelium, the virus was released from the apical surface; when applied to basolateral surface,more »« less
DOI: 10.1016/j.virol.2008.09.030
High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model

Journal Article Jiangmei, Yin ; Anlan, Dai ; Laddy, Dominick J ; ... - Virology

Interleukin (IL)-15, is a cytokine that is important for the maintenance of long-lasting, high-avidity T cell response to invading pathogens and has, therefore, been used in vaccine and therapeutic platforms as an adjuvant. In addition to pure protein delivery, plasmids encoding the IL-15 gene have been utilized. However, it is critical to determine the appropriate dose to maximize the adjuvanting effects. We immunized rhesus macaques with different doses of IL-15 expressing plasmid in an influenza non-human primate immunogenicity model. We found that co-immunization of rhesus macaques with a Flu DNA-based vaccine and low doses of plasmid encoding macaque IL-15 enhancedmore »« less
A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates

Journal Article Keeffe, Jennifer R. ; Van Rompay, Koen K. A. ; Olsen, Priscilla C. ; ... - Cell Reports
Cited by 10
DOI: 10.1016/j.celrep.2018.10.031
A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates

Journal Article Keeffe, Jennifer R. ; Van Rompay, Koen K. A. ; Olsen, Priscilla C. ; ... - Cell Reports
DOI: 10.1016/j.celrep.2018.10.031
EFFECT OF ROUTE OF ADMINISTRATION OF VACCINE AND CHALLENGE ON THE IMMUNOGENIC EFFICIENCY OF DOUBLE VACCINATION WITH IRRADIATED ANCYLOSTOMA CANINUM LARVAE.

Journal Article Miller, T A - J. Parasitol., 50: 200-6(Apr. 1965).
DOI: 10.2307/3276081

Similar Records